Retatrutide

Retatrutide 구조식 이미지
카스 번호:
2381089-83-2
상품명:
Retatrutide
동의어(영문):
LY3437943;Retalutide;etatrutide;Retatrutid;GIPR/GLP-1R;Retatrutide;Retaglutide;Retatratide;Ritaglutide;Retatrutide Na
CBNumber:
CB912574543
분자식:
포뮬러 무게:
0
MOL 파일:
Mol file

Retatrutide 속성

저장 조건
-20°C
물리적 상태
가루
색상
White lyophilized
수용성
Soluble in water (5mg/ml).

안전

Retatrutide C화학적 특성, 용도, 생산

개요

Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide inhibits human GCGR, GIPR and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively and mouse GCGR, GIPR, and GLP-1R with EC50 values of 2.32, 0.191 and 0.794 nM, respectively. It is an important tool for obesity research.
Retatrutide potently activates the GLP-1R signaling pathway to stimulate glucose-dependent insulin secretion through activity at the GIP receptor (GIPR) or the GLP-1R.
Retatrutide is a synthetic peptide with glucose-lowering effects. It is an antidiabetic agent against type 2 diabetes (T2D), stimulating insulin and suppressing glucagon secretion in a glucose-dependent manner.
Retatrutide was also shown to delay gastric emptying, lower fasting and postprandial glucose concentration, decrease food intake and reduce body weight in patients with type 2 diabetes.

생물학적 활성

Retatrutide (LY3437943), a single peptide conjugated to a lipid diacid molecule, exerts a powerful agonist effect on the human glucagon‐receptor (GCGR), GIPR, and GLP‐1R. In comparison with the human glucagon and glucagon‐like peptide 1 (GLP‐1), retatrutide exhibits reduced potency (by a factor of 0.3 and 0.4, respectively) on the GCGR and GLP‐1R while displaying enhanced potency at the human GIPR (by a factor of 8.9) when compared to the glucose‐dependent insulinotropic polypeptide (GIP)[7].

부작용

The most common side effects of retatrutide are gastrointestinal, including: Nausea, Diarrhea, Vomiting, and Constipation. At higher doses, researchers stated these symptoms were "mostly mild to moderate in severity" and typically treated by lowering the dosage. However, 7% of patients also experienced skin tingling. At 24 weeks of treatment, patients' heart rates on higher doses peaked but declined afterward.

Retatrutide 준비 용품 및 원자재

원자재

준비 용품


Retatrutide 공급 업체

글로벌( 226)공급 업체
공급자 전화 이메일 국가 제품 수 이점
Shanghai Longyu Biotechnology Co., Ltd.
+8619521488211
info@longyupharma.com China 2556 58
Hubei Yuanao Technology CO Ltd
+86-15377628618
info@yuanaotech.com China 6 58
Huaian Banting Trading Co., Ltd.
+8615833979905
sales2@bantingpeptide.com China 85 58
Hebei Xunou new energy Technology Co., LTD
+86-17531957005; +undefined17531957005
xunou8@hbxunou.com China 36 58
Hebei Lingding Biotechnology Co., Ltd.
+86-18134017493
sunflowerfranklin20@gmail.com China 14 58
Sea Biological Co.,LTD
+8613865152372
tim@sea-biol.com China 71 58
Hangzhou Hyper Chemicals Limited
+86-0086-57187702781 +8613675893055
info@hyper-chem.com China 295 58
Shaanxi Xianhe Biotech Co., Ltd
+86-17709210191; +8617709210191
Jerry@xhobio.com China 884 58
S&Y Biochem Co.,Ltd
+86-17774091612; +8617774091612
marketing@sybiochem.com China 295 58
Hubei KDG Web Science&Technology Co., Ltd
18672314556 +8618672314556
sales@kdg-tech.com China 933 58

Copyright 2019 © ChemicalBook. All rights reserved